Pharmaceuticals, Biotechnology and Life Sciences
Compound Designed to Enhance Synaptic Integrity and Improve Learning, Memory and Function CAMBRIDGE, Mass.–(BUSINESS WIRE)–Rodin Therapeutics today announced positive Phase…
GenSIght will present results from the REVERSE Phase III clinical trial of GS010 at the 2019 American Academy of Neurology (AAN) Annual Meeting
Long assumed to be a mere “relay,” an often-overlooked egg-like structure in the middle of the brain also turns out to play a pivotal role in tuning-up thinking circuity. A trio of studies in mice funded by the National Institutes of Health are revealing that the thalamus sustains the ability to distinguish categories and hold thoughts in mind.
National Institutes of Health (NIH)-funded neuroscientists have created a 3D window into the human brain’s budding executive hub assembling itself during a critical period in prenatal development. What’s more, they used it to discover and experimentally correct — in a petri dish — defective cell migration caused by an autism-related disorder.
U.S. Food and Drug Administration(FDA) has accepted for review the Alexion Pharmaceuticals’s supplemental Biologics License Application (sBLA) to extend the indication for Soliris (eculizumab) as a potential treatment for patients with refractory generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.
Argenx, a European biopharmaceutical company focused on drugs for the treatment of cancer and autoimmune diseases, has initiated a Phase…
Horizon Pharma has announced that the Phase 3 trial, Steadfast (Safety, Tolerability and Efficacy of Actimmune Dose Escalation in Friedreich’s Ataxia study), evaluating Actimmune (interferon gamma-1b) for…